Literature DB >> 11748936

Chemo-cryo combination therapy: an adjunctive model for the treatment of prostate cancer.

D M Clarke1, J M Baust, R G Van Buskirk, J G Baust.   

Abstract

Despite continuing research and the development of alternate therapeutic options, prostate cancer remains problematic. Chemotherapy has played a minor role as a treatment option due to its lack of efficacy. Whereas cryotherapy has received renewed attention as a treatment modality, it too fails to offer an absolute curative option. Previously, we reported on the utilization of a therapeutic model, which, in combination, increases cell death in a canine renal cell model. Based upon that study, we investigated a combination therapy model as an alternative for the treatment modality for prostate cancer. We hypothesized that the combination of chemotherapy and cryosurgery would result in enhanced cell death, thereby presenting a more effective treatment of prostate cancer. A human prostate cancer cell (PC-3) model was exposed to 5-fluorouracil (5-FU) for 2 and 4 days (prefreeze), freezing (-5 to -100 degrees C), or a combination of the two treatments, and each was assessed for effectiveness over a 2-week posttreatment period. Additionally, investigation into the mechanisms of cell death initiated by the respective therapies was performed through DNA cleavage analysis. For chemotherapy, cultures exposed to 5-FU (2-4 days) yielded a 15-25% loss in cell survival. For cryotherapy, cultures exposed to a temperature window of -5 to -20 degrees C yielded an initial 5-70% loss of viability but cells propagated over time. Cultures exposed to temperatures of -25 to -80 degrees C yielded a 90-99% (+/-4.5%) initial loss in viability with repopulation observed by 12 days postthaw. Cells frozen to -100 degrees C yielded 100% (+/-0.3%) loss of viability and exhibited no signs of propagation. For chemo-cryo therapy, combination treatment at milder temperatures (-5 to -25 degrees C) resulted in an enhanced loss of cell viability compared to that for either treatment alone. Combination treatment at lower temperatures (-40 to -80 degrees C) resulted in a complete loss of cell viability. DNA fragmentation analysis at 48 h posttreatment revealed that dead (detached) cells treated with 5-FU died primarily through apoptosis, whereas dead cells from freezing (-15 degrees C) alone died primarily through freeze-rupture and necrosis. Detached cell analysis from combination treatment at -15 degrees C revealed the presence of apoptotic, necrotic, and freeze-rupture cell death. Scanning electron micrographs of cells exposed to freezing contributing to cell death. These data demonstrate that the combination of 5-FU at sublethal doses and freezing temperatures improves human prostate cancer cell death efficacy. Further, we suggest that chemo-cryo therapy offers a potential alternative treatment for the control and eradication of prostate cancer. Copyright 2001 Elsevier Science.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11748936     DOI: 10.1006/cryo.2001.2333

Source DB:  PubMed          Journal:  Cryobiology        ISSN: 0011-2240            Impact factor:   2.487


  26 in total

1.  Nanotechnology for energy-based cancer therapies.

Authors:  Kyle Gilstrap; Xiaoxiao Hu; Xiongbin Lu; Xiaoming He
Journal:  Am J Cancer Res       Date:  2011-03-11       Impact factor: 6.166

Review 2.  Cryotherapy.

Authors:  Katsuto Shinohara
Journal:  Int J Clin Oncol       Date:  2007-12-21       Impact factor: 3.402

3.  Vitamin D(3) cryosensitization increases prostate cancer susceptibility to cryoablation via mitochondrial-mediated apoptosis and necrosis.

Authors:  John M Baust; Daniel P Klossner; Anthony Robilotto; Robert G Vanbuskirk; Andrew A Gage; Vladimir Mouraviev; Thomas J Polascik; John G Baust
Journal:  BJU Int       Date:  2011-08-26       Impact factor: 5.588

Review 4.  Re-purposing cryoablation: a combinatorial 'therapy' for the destruction of tissue.

Authors:  J G Baust; J C Bischof; S Jiang-Hughes; T J Polascik; D B Rukstalis; A A Gage; J M Baust
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-01-27       Impact factor: 5.554

5.  Surgical cryoablation as an option for small renal masses in patients who are not ideal partial nephrectomy candidates: intermediate-term outcomes.

Authors:  Venu Chalasani; Carlos H Martinez; Darwin Lim; Mazen Abdelhady; Joseph L Chin
Journal:  Can Urol Assoc J       Date:  2010-12       Impact factor: 1.862

6.  Effects of freezing on intratumoral drug transport.

Authors:  Bumsoo Han; Ka Yaw Teo
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2009

Review 7.  Experimental cryosurgery investigations in vivo.

Authors:  A A Gage; J M Baust; J G Baust
Journal:  Cryobiology       Date:  2009-10-13       Impact factor: 2.487

Review 8.  Mechanisms of cryoablation: clinical consequences on malignant tumors.

Authors:  J G Baust; A A Gage; T E Bjerklund Johansen; J M Baust
Journal:  Cryobiology       Date:  2013-11-13       Impact factor: 2.487

9.  Optimisation and molecular signalling of apoptosis in sequential cryotherapy and chemotherapy combination in human A549 lung cancer xenografts in SCID mice.

Authors:  V Forest; R Hadjeres; R Bertrand; R Jean-François
Journal:  Br J Cancer       Date:  2009-05-19       Impact factor: 7.640

10.  Integrin involvement in freeze resistance of androgen-insensitive prostate cancer.

Authors:  J G Baust; D P Klossner; R G Vanbuskirk; A A Gage; V Mouraviev; T J Polascik; J M Baust
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-01-12       Impact factor: 5.554

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.